IMC-202

N/A

Report date: 2025/06/12 15:42:55

Base Information

Drug NameIMC-202
Drug Alias NameIMC-202YH-41723IMC-2102
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionProgrammed death-ligand 1 blockersT cell immunoglobulin and ITIM domains inhibitors
TargetsProgrammed death-ligand 1T cell immunoglobulin and ITIM domains
Therapy Area/IndicationsSolid tumoursUrinary Bladder NeoplasmsCarcinoma, Non-Small-Cell Lung +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSouth Korea
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesImmuneoncia Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesImmuneoncia Therapeutics Inc
Inactive CompaniesSorrento Therapeutics Inc
Active IndicationsSolid tumoursUrinary Bladder NeoplasmsCarcinoma, Non-Small-Cell Lung +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A